Literature DB >> 7011219

Antibiotic prophylaxis with cefoxitin in colorectal surgery: effect on the colon microflora and septic complications--a clinical model for prediction of the benefit and risks in using a new antibiotic in prophylaxis.

L Kager, I Ljungdahl, A S Malmborg, C E Nord, R Pieper, P Dahlgren.   

Abstract

Cefoxitin was administered parenterally in doses of 2 g, every six hours for two days, to 20 patients undergoing colorectal surgery. Blood and fecal specimens were obtained for five days for analysis of cefoxitin concentrations. Tissue samples from the gut wall were obtained at surgery. The maximum serum concentrations during surgery varied between 25 and 100 microgram/ml, and the cefoxitin concentrations for the fecal samples were 1.5-35 microgram/g and for the tissue samples, 2.0-50 microgram/g. Fecal samples for cultivation of aerobic and anaerobic bacteria were also obtained daily during the first five days, and after 14 day after operation. Pronounced changes in the microflora occurred during the investigation period. Among the aerobic bacteria, cefoxitin-sensitive Escherichia coli and other enterobacteria decreased markedly while cefoxitin-resistant enterococci, Pseudomonas and Enterobacter proliferated during the antibiotic prophylaxis period. Among the anaerobic bacteria, Bacteroides fragilis and other Gram-negative bacteria decreased significantly. However, after the antibiotic administration period, all cefoxitin-resistant strains decreased while the suppressed E. coli and B. fragilis strains increased. In one patient, a minor postoperative infection caused by a cefoxitin-resistant strain of Pseudomonas aeruginosa was observed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7011219      PMCID: PMC1345062          DOI: 10.1097/00000658-198103000-00005

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  9 in total

1.  Some properties of coagulase-negative deoxyribonuclease-producing strains of staphylococci from human infections.

Authors:  K Dornbusch; C E Nord; B Olsson; T Wadström
Journal:  Med Microbiol Immunol       Date:  1976-06-01       Impact factor: 3.402

2.  Evaluation of two test-kits--API and Oxi Ferm tube--for identification of oxidative-fermentative Gram-negative rods.

Authors:  C E Nord; B Wretlind; A Dahlbäck
Journal:  Med Microbiol Immunol       Date:  1977-07-18       Impact factor: 3.402

3.  Presumptive identification of group A, B, and D streptococci.

Authors:  R R Facklam; J F Padula; L G Thacker; E C Wortham; B J Sconyers
Journal:  Appl Microbiol       Date:  1974-01

4.  Antibiotic sensitivity testing. Report of an international collaborative study.

Authors:  H M Ericsson; J C Sherris
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1971

5.  Evaluation of five test-kits-API, AuxoTab, Enterotube, PathoTec and R-B-for identification of Enterobacteriaceae.

Authors:  C E Nord; A A Lindberg; A Dahlbäck
Journal:  Med Microbiol Immunol       Date:  1974-03-22       Impact factor: 3.402

6.  Comparison between systemic and oral antimicrobial prophylaxis in colorectal surgery.

Authors:  M R Keighley; Y Arabi; J Alexander-Williams; D Youngs; D W Burdon
Journal:  Lancet       Date:  1979-04-28       Impact factor: 79.321

7.  Rapid grouping of streptococci by immunoelectroosmophoresis.

Authors:  T Wadström; C E Nord; A A Lindberg; R Möllby
Journal:  Med Microbiol Immunol       Date:  1974-03-22       Impact factor: 3.402

8.  Microbial synergy in experimental intra-abdominal abscess.

Authors:  A B Onderdonk; J G Bartlett; T Louie; N Sullivan-Seigler; S L Gorbach
Journal:  Infect Immun       Date:  1976-01       Impact factor: 3.441

Review 9.  Cefoxitin and cephamycins: microbiological studies.

Authors:  E O Stapley; J Birnbaum; A K Miller; H Wallick; D Hendlin; H B Woodruff
Journal:  Rev Infect Dis       Date:  1979 Jan-Feb
  9 in total
  22 in total

Review 1.  The intestinal microbiome and surgical disease.

Authors:  Monika A Krezalek; Kinga B Skowron; Kristina L Guyton; Baddr Shakhsheer; Sanjiv Hyoju; John C Alverdy
Journal:  Curr Probl Surg       Date:  2016-06-14       Impact factor: 1.909

2.  Imipenem concentrations in colorectal surgery and impact on the colonic microflora.

Authors:  L Kager; B Brismar; A S Malmborg; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

3.  Effect of aztreonam on the colon microflora in patients undergoing colorectal surgery.

Authors:  L Kager; B Brismar; A S Malmborg; C E Nord
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

Review 4.  Cephalosporin-probenecid drug interactions.

Authors:  G R Brown
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 5.  Antibiotic trials in intra-abdominal infections. A critical evaluation of study design and outcome reporting.

Authors:  J S Solomkin; J L Meakins; M D Allo; E P Dellinger; R L Simmons
Journal:  Ann Surg       Date:  1984-07       Impact factor: 12.969

Review 6.  Adverse reactions and interactions with newer cephalosporin and cephamycin antibiotics.

Authors:  S R Norrby
Journal:  Med Toxicol       Date:  1986 Jan-Feb

7.  The effect of piperacillin prophylaxis on the colonic microflora In patients undergoing colorectal surgery.

Authors:  L Kager; A S Malmborg; C E Nord; S Sjöstedt
Journal:  Infection       Date:  1983 Sep-Oct       Impact factor: 3.553

8.  Non-observance of guidelines for surgical antimicrobial prophylaxis and surgical-site infections.

Authors:  S Lallemand; M Thouverez; P Bailly; X Bertrand; D Talon
Journal:  Pharm World Sci       Date:  2002-06

9.  Ciprofloxacin concentrations and impact of the colon microflora in patients undergoing colorectal surgery.

Authors:  B Brismar; C Edlund; A S Malmborg; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 10.  Colonization resistance of the human intestinal microflora: testing the hypothesis in normal volunteers.

Authors:  S L Gorbach; M Barza; M Giuliano; N V Jacobus
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.